Latest Conference Articles

March 12th 2018, 9:11pm

PER® Winter Lung Cancer Conference

Upfront testing for BRAF V600E mutations is necessary for patients with non–small cell lung cancer, but if results are positive, physicians are unsure when to administer BRAF/MEK combination therapy—and they must be prepared to manage the associated adverse events.

March 12th 2018, 1:11am

PER® Miami Breast Cancer Conference

Abemaciclib (Verzenio) has quickly amassed several clinical indications for patients with metastatic breast cancer, and is the only CDK4/6 inhibitor approved as a single agent.

March 11th 2018, 8:27pm

PER® Miami Breast Cancer Conference

Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, and chair of the Miami Breast Cancer Conference, discusses the evolution of breast cancer treatment in recent years. Borgen shared his insight in an interview during the meeting.

March 11th 2018, 5:25am

PER® Winter Lung Cancer Conference

Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.

March 11th 2018, 3:41am

PER® Winter Lung Cancer Conference

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses advancements in the management of immune-related adverse events (irAEs) in patients with lung cancer during the 5th Annual Miami Lung Cancer Conference.

March 11th 2018, 3:05am

PER® Miami Breast Cancer Conference

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses novel agents that are emerging in the HER2-positive breast cancer space. Hurvitz shared this insight in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.

March 11th 2018, 2:57am

PER® Winter Lung Cancer Conference

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in the first-line treatment of non–small cell lung cancer during the 5th Annual Miami Lung Cancer Conference.

March 11th 2018, 2:49am

PER® Winter Lung Cancer Conference

Immune-based therapies continue to show promising signals for patients with small cell lung cancer and mesothelioma, but better predictive biomarkers are needed to determine who is most likely to benefit.

March 11th 2018, 2:40am

PER® Miami Breast Cancer Conference

Endocrine therapy can achieve tumor reduction for patients with ER-positive breast cancer, possibly avoiding the need for chemotherapy or even surgery in some patients; however, deciding how long to continue this therapy can be tricky.

March 11th 2018, 2:32am

PER® Miami Breast Cancer Conference

The latest revision of the staging manual for breast cancer from the American Joint Committee on Cancer is a quantum leap toward precision oncology, as it codifies advanced knowledge of the role of biologic factors in cancer, and oncologists should now be using it.

March 11th 2018, 2:09am

PER® Winter Lung Cancer Conference

With durvalumab (Imfinzi) being hailed as a potentially practice changing therapy in locally advanced non–small cell lung cancer, ongoing studies are seeking to determine the efficacy of immunotherapy in earlier stages of disease.

March 11th 2018, 1:41am

PER® Miami Breast Cancer Conference

The PARP inhibitors have finally become available for patients with BRCA-mutant metastatic breast cancer, ushering in a potential new era for targeted therapies with studies currently ongoing in the adjuvant setting and exploring combinations.

March 11th 2018, 1:16am

PER® Miami Breast Cancer Conference

The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.

March 10th 2018, 6:25pm

PER® Miami Breast Cancer Conference

Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.

March 9th 2018, 9:35pm

PER® Miami Breast Cancer Conference

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses an exploratory analysis of the OlympiAD trial for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.

March 9th 2018, 8:40pm

PER® Miami Breast Cancer Conference

Palbociclib (Ibrance) demonstrated significant efficacy in combination with letrozole (Femara) in the frontline setting of estrogen receptor-positive, HER2-negative, postmenopausal metastatic breast cancer.

March 9th 2018, 5:22pm

PER® Miami Breast Cancer Conference

Fabrice André, MD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the remaining questions with immunotherapy agents as potential therapy for patients with triple-negative breast cancer. Andre expanded on this in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.

March 9th 2018, 5:19pm

PER® Miami Breast Cancer Conference

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the utilization of genetic testing in breast cancer to identify actionable results for patients.

March 9th 2018, 5:21am

PER® Miami Breast Cancer Conference

The progression-free survival benefit for ribociclib in pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer was sustained across patient subgroups, according to findings from the phase III MONALEESA-7 trial.

March 8th 2018, 10:31pm

PER® Miami Breast Cancer Conference

Improvements in progression-free survival with olaparib (Lynparza) remained consistent regardless of baseline tumor burden for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.